Rheumatoid vasculitis is a rare, serious extra-articular complication of rheumatoid arthritis in which immune-mediated necrotizing or leukocytoclastic vasculitis affects small and medium-sized vessels. It occurs mainly in severe seropositive rheumatoid arthritis and most often manifests in skin and peripheral nerves, with potential systemic ischemic organ injury.
Ask a research question about Rheumatoid Vasculitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Rheumatoid Vasculitis
creation_date: "2026-05-07T02:01:26Z"
updated_date: "2026-05-07T02:01:26Z"
description: >-
Rheumatoid vasculitis is a rare, serious extra-articular complication of
rheumatoid arthritis in which immune-mediated necrotizing or
leukocytoclastic vasculitis affects small and medium-sized vessels. It occurs
mainly in severe seropositive rheumatoid arthritis and most often manifests
in skin and peripheral nerves, with potential systemic ischemic organ injury.
category: Complex
disease_term:
preferred_term: rheumatoid vasculitis
term:
id: MONDO:0043267
label: rheumatoid vasculitis
parents:
- Rheumatoid arthritis
- Autoimmune vasculitis
synonyms:
- Systemic rheumatoid vasculitis
- Vasculitis associated with rheumatoid arthritis
- Vasculitides, rheumatoid
- vasculitis, rheumatoid
prevalence:
- population: rheumatoid arthritis
notes: >-
Rheumatoid vasculitis is now rare and appears to be decreasing in modern
rheumatoid arthritis cohorts, but older clinical and autopsy estimates vary
widely.
evidence:
- reference: PMID:25405822
reference_title: "Rheumatoid vasculitis: an update."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The incidence of rheumatoid vasculitis has declined significantly in the past several decades, but morbidity and mortality continue to remain high, despite aggressive treatment with cyclophosphamide or biologic agents.
explanation: This review supports declining rheumatoid vasculitis incidence while preserving its serious clinical impact.
progression:
- phase: rheumatoid arthritis complication
notes: >-
Rheumatoid vasculitis usually develops after established rheumatoid
arthritis, but once systemic vasculitis appears it is associated with
substantial relapse and mortality.
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The median age at presentation was 63 years and the median duration of RA was 10.8 years.
explanation: This Mayo Clinic case-control series supports adult onset after long-standing rheumatoid arthritis.
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thirty-six per cent relapsed by 5 years and 26% died.
explanation: This provides relapse and mortality outcomes in a modern tertiary-center rheumatoid vasculitis cohort.
pathophysiology:
- name: Seropositive rheumatoid autoimmune substrate
description: >-
Rheumatoid vasculitis arises primarily in severe seropositive rheumatoid
arthritis, where rheumatoid factor, anti-CCP antibodies, HLA-associated
susceptibility, and tobacco exposure mark an immune context that can
support extra-articular vascular disease.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: adaptive immune response
modifier: ABNORMAL
term:
id: GO:0002250
label: adaptive immune response
downstream:
- target: Immune-complex and cellular vascular inflammation
description: Seropositive systemic rheumatoid autoimmunity provides immune complexes and cellular immune mechanisms that can target vessel walls.
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The majority were seropositive and had elevated inflammatory markers.
explanation: This supports seropositive systemic inflammation as a common context in rheumatoid vasculitis cases.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Seropositivity, specific HLA variations, and tobacco use are among the genetic and environmental predictors of rheumatoid vasculitis.
explanation: This review links seropositivity, HLA variation, and smoking to rheumatoid vasculitis risk.
- name: Immune-complex and cellular vascular inflammation
description: >-
Autoantibody-rich rheumatoid inflammation can drive immune-complex disease
and inflammatory cell recruitment in small and medium-sized vessel walls,
producing necrotizing or leukocytoclastic vasculitis.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: neutrophil
term:
id: CL:0000775
label: neutrophil
biological_processes:
- preferred_term: complement activation, classical pathway
modifier: INCREASED
term:
id: GO:0006958
label: complement activation, classical pathway
- preferred_term: leukocyte chemotaxis
modifier: INCREASED
term:
id: GO:0030595
label: leukocyte chemotaxis
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
downstream:
- target: Vessel-wall destruction
description: Vessel-wall inflammation leads to necrosis, leukocytoclasis, and vascular structural damage.
evidence:
- reference: PMID:28631066
reference_title: "Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Rheumatoid vasculitis (RV) is an unusual complication of long-standing rheumatoid arthritis, which is characterized by the development of necrotizing or leukocytoclastic vasculitis involving small or medium-sized vessels.
explanation: This directly defines rheumatoid vasculitis as necrotizing or leukocytoclastic small- or medium-vessel vasculitis.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
suggests that immune complex disease may be causative
explanation: This supports immune-complex biology as a proposed pathogenic mechanism.
- name: Vessel-wall destruction
description: >-
Involved small and medium vessels show inflammatory infiltration of the
vessel wall with destructive changes such as necrosis, leukocytoclasis, and
elastic-lamina disruption.
cell_types:
- preferred_term: neutrophil
term:
id: CL:0000775
label: neutrophil
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
downstream:
- target: Ischemic tissue injury
description: Destructive vasculitis compromises blood flow and produces tissue ischemia or organ-specific injury.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pathologic features of rheumatoid vasculitis include mononuclear cells or neutrophilic infiltration of the vessel wall of small and medium vessels.
explanation: This supports inflammatory cell infiltration of small and medium vessel walls.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Features of vessel wall destruction are often found, including necrosis, leukocytoclasis, and disruption of the internal and external elastic lamina.
explanation: This directly supports destructive histopathologic vessel-wall injury.
- name: Ischemic tissue injury
description: >-
Vascular inflammation and vessel-wall destruction cause tissue damage or
ischemia in affected territories, producing skin ulcers, digital ischemia or
necrosis, peripheral neuropathy, and less commonly major internal organ
ischemia.
downstream:
- target: Cutaneous vasculitic lesions
description: Ischemic vascular injury in skin produces purpura, ulcers, and digital necrosis.
- target: Vasculitic peripheral neuropathy
description: Ischemic injury to nerve blood supply produces peripheral neuropathy or mononeuritis multiplex.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we define rheumatoid vasculitis as a clinicopathologic manifestation of RA characterized by tissue damage or ischemia verified pathologically by vasculitis.
explanation: This links rheumatoid vasculitis to tissue damage or ischemia.
- reference: PMID:17023257
reference_title: "Systemic rheumatoid vasculitis: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has a vast array of clinical manifestations with a predilection for the skin (peripheral gangrene, deep cutaneous ulcers) and the peripheral nervous system (mononeuritis multiplex).
explanation: This links ischemic tissue injury to the major skin and peripheral nerve manifestations.
histopathology:
- name: Necrotizing or leukocytoclastic small- and medium-vessel vasculitis
diagnostic: true
description: >-
Diagnostic tissue pathology may show necrotizing or leukocytoclastic
vasculitis involving small or medium vessels, with inflammatory vessel-wall
infiltration and destructive vascular changes.
finding_term:
preferred_term: necrotizing or leukocytoclastic vasculitis
evidence:
- reference: PMID:28631066
reference_title: "Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Rheumatoid vasculitis (RV) is an unusual complication of long-standing rheumatoid arthritis, which is characterized by the development of necrotizing or leukocytoclastic vasculitis involving small or medium-sized vessels.
explanation: This supports necrotizing or leukocytoclastic vasculitis as the core histopathologic lesion.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Characteristic histopathology confirmation of vasculitis is generally necessary for a diagnosis of rheumatoid vasculitis.
explanation: This supports histopathology as an important diagnostic standard.
phenotypes:
- category: Cardiovascular
name: Necrotizing small- and medium-vessel vasculitis
diagnostic: true
description: Necrotizing or leukocytoclastic vasculitis of small and medium vessels is the defining vascular phenotype.
phenotype_term:
preferred_term: Vasculitis
term:
id: HP:0002633
label: Vasculitis
evidence:
- reference: PMID:28631066
reference_title: "Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Rheumatoid vasculitis (RV) is an unusual complication of long-standing rheumatoid arthritis, which is characterized by the development of necrotizing or leukocytoclastic vasculitis involving small or medium-sized vessels.
explanation: This directly supports the defining vascular phenotype.
- category: Dermatologic
name: Cutaneous vasculitis
description: Cutaneous vasculitis is the most common presentation in a modern Mayo Clinic case-control series.
phenotype_term:
preferred_term: Cutaneous vasculitis
term:
id: HP:0002633
label: Vasculitis
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cutaneous vasculitis was the most common presentation, followed by vasculitic neuropathy.
explanation: This supports skin vasculitis as the most common presentation in this cohort.
- category: Dermatologic
name: Deep cutaneous ulcers
description: Deep skin ulcers are a characteristic cutaneous manifestation of rheumatoid vasculitis.
phenotype_term:
preferred_term: Skin ulcer
term:
id: HP:0200042
label: Skin ulcer
evidence:
- reference: PMID:17023257
reference_title: "Systemic rheumatoid vasculitis: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has a vast array of clinical manifestations with a predilection for the skin (peripheral gangrene, deep cutaneous ulcers) and the peripheral nervous system (mononeuritis multiplex).
explanation: This supports deep cutaneous ulcers as a major skin manifestation.
- category: Dermatologic
name: Digital ischemia
description: Digital ischemia can result from severe distal vasculitic vascular compromise.
phenotype_term:
preferred_term: Digital ischemia
term:
id: HP:0033402
label: Digital ischemia
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cutaneous manifestations of rheumatoid vasculitis include palpable purpura, nodules, ulcers (Fig. 1), and digital necrosis [23].
explanation: Digital necrosis supports severe distal ischemic cutaneous involvement.
- category: Dermatologic
name: Peripheral gangrene
description: Peripheral gangrene reflects severe ischemic cutaneous involvement.
phenotype_term:
preferred_term: Gangrene
term:
id: HP:0100758
label: Gangrene
evidence:
- reference: PMID:17023257
reference_title: "Systemic rheumatoid vasculitis: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has a vast array of clinical manifestations with a predilection for the skin (peripheral gangrene, deep cutaneous ulcers) and the peripheral nervous system (mononeuritis multiplex).
explanation: This directly supports peripheral gangrene as a skin manifestation.
- category: Dermatologic
name: Palpable purpura
description: Palpable purpura is part of the cutaneous manifestation spectrum.
phenotype_term:
preferred_term: Purpura
term:
id: HP:0000979
label: Purpura
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cutaneous manifestations of rheumatoid vasculitis include palpable purpura, nodules, ulcers (Fig. 1), and digital necrosis [23].
explanation: This directly lists palpable purpura among cutaneous manifestations.
- category: Dermatologic
name: Livedo reticularis
description: Livedo reticularis can be seen in rheumatoid vasculitis but is nonspecific.
phenotype_term:
preferred_term: Livedo reticularis
term:
id: HP:0033505
label: Livedo reticularis
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Livedo reticularis is commonly seen, although it is nonspecific and is found in multiple other disorders.
explanation: This supports livedo reticularis as a recognized but nonspecific cutaneous finding.
- category: Neurological
name: Vasculitic neuropathy
description: Peripheral nerve involvement is a common and classic severe manifestation.
phenotype_term:
preferred_term: Peripheral neuropathy
term:
id: HP:0009830
label: Peripheral neuropathy
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cutaneous vasculitis was the most common presentation, followed by vasculitic neuropathy.
explanation: This supports vasculitic neuropathy as a common presentation after cutaneous disease.
- reference: PMID:28631066
reference_title: "Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The most common organs involved are the skin and peripheral nerve.
explanation: This supports peripheral nerve involvement as a major organ target.
- category: Neurological
name: Mononeuritis multiplex
description: Mononeuritis multiplex is a specific peripheral nervous system presentation of systemic vasculitis.
phenotype_term:
preferred_term: Mononeuritis multiplex
term:
id: HP:0032018
label: Multiple mononeuropathy
evidence:
- reference: PMID:17023257
reference_title: "Systemic rheumatoid vasculitis: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has a vast array of clinical manifestations with a predilection for the skin (peripheral gangrene, deep cutaneous ulcers) and the peripheral nervous system (mononeuritis multiplex).
explanation: This directly supports mononeuritis multiplex as a peripheral nervous system manifestation.
- category: Ophthalmologic
name: Inflammatory ocular disease
description: Ocular inflammatory disease can occur in systemic rheumatoid vasculitis.
phenotype_term:
preferred_term: Inflammatory abnormality of the eye
term:
id: HP:0100533
label: Inflammatory abnormality of the eye
frequency: OCCASIONAL
evidence:
- reference: PMID:31203225
reference_title: "Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RV presented in the skin in 8 patients (47%), as mononeuritis multiplex in 2 (12%), inflammatory ocular disease in 2 (12%), and affected multiple organ systems in 5 (29%).
explanation: This cohort quantifies inflammatory ocular disease in rituximab-treated systemic RV.
- category: Constitutional
name: Fever
description: Fever is a constitutional feature that should raise suspicion when combined with extra-articular RA and skin or nervous system abnormalities.
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Discovering skin or nervous system abnormalities in a patient with extra-articular manifestations of RA and constitutional symptoms (eg, weight loss or fever) should raise a high index of suspicion for rheumatoid vasculitis and must prompt further evaluation.
explanation: This supports fever as a relevant constitutional symptom in the diagnostic context.
- category: Constitutional
name: Weight loss
description: Weight loss is a constitutional feature in the clinical context of suspected rheumatoid vasculitis.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Discovering skin or nervous system abnormalities in a patient with extra-articular manifestations of RA and constitutional symptoms (eg, weight loss or fever) should raise a high index of suspicion for rheumatoid vasculitis and must prompt further evaluation.
explanation: This supports weight loss as a relevant constitutional symptom in the diagnostic context.
biochemical:
- name: Seropositive rheumatoid autoantibodies
presence: Positive
context: Rheumatoid factor and anti-CCP antibodies support, but do not definitively diagnose, rheumatoid vasculitis in the right clinical context.
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The majority were seropositive and had elevated inflammatory markers.
explanation: This supports seropositivity and inflammation as common laboratory features.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Conversely, a lack of rheumatoid autoantibodies may confer a negative predictive value for rheumatoid vasculitis, as one study showed that more than 90% of patients with rheumatoid vasculitis had anti-CCP antibodies, compared with 7% of patients with other types of systemic vasculitis [7].
explanation: This supports anti-CCP seropositivity as a useful supportive marker and anti-CCP negativity as evidence against RV.
- name: Elevated inflammatory markers
presence: Positive
context: ESR and CRP elevation can support active systemic inflammation but are not specific for rheumatoid vasculitis.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Laboratory findings may include anemia of chronic inflammation, elevation of erythrocyte sedimentation rate or C-reactive protein, polyclonal hypergammaglobulinemia, and RA-associated autoantibodies.
explanation: This supports ESR/CRP elevation and other inflammatory laboratory findings.
- name: Decreased complement during active disease
presence: Positive
context: Complement levels may fall dynamically during active disease and can help follow activity.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Complement levels may be dynamically decreased during active disease and, along with inflammatory parameters, may provide useful follow-up information.
explanation: This supports complement consumption as a supportive activity marker.
genetic:
- name: HLA shared-epitope susceptibility
association: Susceptibility association
relationship_type: RISK_FACTOR
notes: >-
HLA-DRB1 shared-epitope genotypes are associated with rheumatoid vasculitis
susceptibility in rheumatoid arthritis, but no deterministic monogenic
cause is established.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A recent meta-analysis that compiled 14 studies encompassing more than 1500 RA patients revealed a striking relationship between rheumatoid vasculitis and three specific genotypes of the HLA-DRB1 shared epitope: *0401/*0401, *0401/*0404, and *0101/*0401 [5].
explanation: This supports HLA-DRB1 shared-epitope genotypes as susceptibility associations.
environmental:
- name: Tobacco smoking
presence: Positive
description: Smoking is an environmental and lifestyle risk factor associated with rheumatoid vasculitis.
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
One third were current smokers.
explanation: This supports smoking exposure among rheumatoid vasculitis cases; the case-control study also reports increased odds for current smoking at RA diagnosis.
- name: Hydroxychloroquine and low-dose aspirin exposure
presence: Negative association
description: >-
Hydroxychloroquine and low-dose aspirin were associated with decreased odds
of rheumatoid vasculitis in one observational case-control study; this is a
protective association, not proof of causality.
chemicals:
- hydroxychloroquine
- acetylsalicylic acid
effect: Associated with decreased odds for developing rheumatoid vasculitis.
evidence:
- reference: PMID:24441152
reference_title: "Vasculitis associated with rheumatoid arthritis: a case-control study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the use of HCQ (OR 0.54, CI 0.31, 0.94) and low-dose aspirin (OR 0.42, CI 0.21, 0.85) was associated with decreased odds for developing RV.
explanation: This directly supports the observational protective association for HCQ and low-dose aspirin.
diagnosis:
- name: Clinicopathologic diagnosis with biopsy when feasible
description: >-
Diagnosis is based on a compatible rheumatoid arthritis context, exclusion
of mimics, and ideally biopsy confirmation of vasculitis in involved skin,
nerve, muscle, or another affected organ.
diagnosis_term:
preferred_term: Diagnostic Procedure
term:
id: NCIT:C18020
label: Diagnostic Procedure
results: Tissue-confirmed vasculitis supports diagnosis and helps justify toxic immunosuppressive therapy.
evidence:
- reference: PMID:17023257
reference_title: "Systemic rheumatoid vasculitis: a review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Because of the lack of specific signs and symptoms, the diagnosis relies on the exclusion of other causes of similar lesions (diabetes, atherosclerosis, drug reactions, infection, neoplasias) and, ideally, on the histopathological demonstration of necrotizing vasculitis.
explanation: This supports exclusion of mimics and histopathologic confirmation as diagnostic pillars.
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Biopsy of skin lesions has the highest yield (up to 75%).
explanation: This supports skin biopsy as a high-yield diagnostic procedure when skin lesions are present.
- name: Electrophysiology-directed nerve or muscle biopsy
description: >-
When neuropathy is suspected, electrophysiologic testing may help localize
abnormalities and direct nerve or muscle biopsy.
diagnosis_term:
preferred_term: Electrophysiologic study
results: Localizes peripheral nerve involvement and may guide biopsy site selection.
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Electrophysiologic study of peripheral nerves may reveal subclinical defects that could be used to direct a biopsy.
explanation: This supports electrophysiology as a diagnostic adjunct in suspected peripheral nerve involvement.
- name: Negative biopsy does not exclude rheumatoid vasculitis
description: >-
Sampling limitations can produce false-negative biopsy results, so negative
histology does not fully exclude rheumatoid vasculitis when clinical
suspicion remains high.
evidence:
- reference: PMID:39036255
reference_title: "Rheumatoid Vasculitis in Modern Era: A Case Report and Comprehensive Literature Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This case highlights the importance of promptly recognizing this rare entity and that a negative biopsy does not rule out RV, and appropriate treatment helps decrease morbidity and mortality.
explanation: This 2024 case-based review supports continued clinical judgment despite a negative biopsy.
treatments:
- name: Glucocorticoids with methotrexate or azathioprine for limited disease
description: >-
Limited or milder disease affecting skin or peripheral nerves may be treated
with systemic glucocorticoids plus methotrexate or azathioprine, balancing
vasculitis control against treatment toxicity.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: prednisone
term:
id: CHEBI:8382
label: prednisone
- preferred_term: methotrexate
term:
id: CHEBI:44185
label: methotrexate
- preferred_term: azathioprine
term:
id: CHEBI:2948
label: azathioprine
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mild rheumatoid vasculitis involving the skin or peripheral nerves can be treated with prednisone and methotrexate or azathioprine.
explanation: This review supports prednisone plus methotrexate or azathioprine for milder skin or peripheral nerve disease.
- name: High-dose glucocorticoids with cyclophosphamide or biologic agents for severe disease
description: >-
Severe systemic or organ-threatening rheumatoid vasculitis may require
higher-dose glucocorticoids and cyclophosphamide or biologic therapy.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: cyclophosphamide
term:
id: CHEBI:4027
label: cyclophosphamide
evidence:
- reference: PMID:20842467
reference_title: "Rheumatoid vasculitis: vanishing menace or target for new treatments?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
More serious organ system involvement may require treatment with higher-dose steroids and cyclophosphamide or biologic agents (Table 2).
explanation: This supports escalation for serious organ involvement.
- name: Rituximab therapy
description: >-
Rituximab is used for induction, relapsing, second-line, salvage, or
combination therapy in systemic rheumatoid vasculitis, with observational
evidence of complete and partial responses within 12 months.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: Rituximab
term:
id: NCIT:C1702
label: Rituximab
evidence:
- reference: PMID:31203225
reference_title: "Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
RTX was used for induction therapy in 8 patients (47%), relapsing RV in 4 (24%), second-line therapy in 2 (12%), and salvage therapy or in combination with another agent in 3 (18%).
explanation: This describes real-world indications for rituximab in systemic RV.
- reference: PMID:31203225
reference_title: "Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Systemic RV is difficult to treat effectively. CR of RV was achieved in 62% and PR in 38% of patients within 12 months of RTX use.
explanation: This supports rituximab response outcomes while preserving the observational evidence context.
references:
- reference: DOI:10.1007/s11926-010-0130-1
title: "Rheumatoid Vasculitis: Vanishing Menace or Target for New Treatments?"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.1007/s11926-017-0667-3
title: "Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.1016/j.semarthrit.2006.04.006
title: "Systemic Rheumatoid Vasculitis: A Review"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.1093/rheumatology/ket475
title: "Vasculitis associated with rheumatoid arthritis: a case-control study"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.1097/bor.0000000000000126
title: "Rheumatoid vasculitis: an update"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.1186/s42358-023-00318-y
title: "Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.3899/jrheum.181397
title: "Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes, and Adverse Events"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.7759/cureus.62783
title: "Rheumatoid Vasculitis in Modern Era: A Case Report and Comprehensive Literature Review"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
- reference: DOI:10.7759/cureus.67346
title: "Rheumatoid vasculitis involving gastrointestinal tract pre-dating rheumatoid arthritis: a case study and literature review"
found_in:
- Rheumatoid_Vasculitis-deep-research-falcon.md
datasets:
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Rheumatoid Vasculitis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Rheumatoid vasculitis (RV) is a rare but severe extra-articular manifestation of rheumatoid arthritis (RA), typically presenting as necrotizing or leukocytoclastic vasculitis involving small-to-medium-sized vessels and associated with high morbidity and mortality. (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5)
Common alternative names in the clinical literature include systemic rheumatoid vasculitis and vasculitis associated with rheumatoid arthritis. (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 1-2)
In this tool run, authoritative ontology/coding identifiers (MONDO, Orphanet, ICD-10/ICD-11, MeSH) were not successfully retrieved from the available sources and therefore cannot be reliably asserted here. RV is represented in the current report using aggregated disease-level literature rather than a specific disease ontology entry. (makol2014vasculitisassociatedwith pages 1-1, makol2015rheumatoidvasculitisan pages 1-2)
Evidence in this report comes primarily from: - Human clinical observational cohorts and case-control studies (e.g., Mayo Clinic series). (makol2014vasculitisassociatedwith pages 1-1, coffey2020rituximabtherapyfor pages 7-9) - Human clinical case series (rituximab-treated cohorts). (coffey2020rituximabtherapyfor pages 2-3, coffey2020rituximabtherapyfor pages 7-9) - Narrative/clinical reviews summarizing clinical and mechanistic understanding. (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) - Recent case-based reviews/case reports (2023–2024) that reflect modern diagnostic challenges (including biopsy-negative presentations). (ahmad2024rheumatoidvasculitisin pages 5-6, ahmad2024rheumatoidvasculitisin media 15865f42)
RV is generally conceptualized as an immune-mediated vascular inflammatory process arising in the context of RA, with both immune-complex/complement-mediated injury and cell-mediated vascular damage contributing. (kishore2017rheumatoidvasculitisa pages 1-2, genta2006systemicrheumatoidvasculitis pages 2-3, kishore2017rheumatoidvasculitisa pages 2-4)
RV is most strongly associated with long-standing, severe, seropositive RA (often erosive/nodular disease). (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5)
In a Mayo Clinic case-control study (2000–2010), factors associated with RV included: - Current smoking at RA diagnosis (OR 1.98). (makol2014vasculitisassociatedwith pages 1-1) - Peripheral vascular disease (OR 3.98). (makol2014vasculitisassociatedwith pages 1-1) - Cerebrovascular disease (OR 6.48). (makol2014vasculitisassociatedwith pages 1-1) - Severe RA (OR 2.02). (makol2014vasculitisassociatedwith pages 1-1) - Use of biologics (OR 2.80), noting important confounding by indication and the challenge of separating “drug-induced vasculitis” from RA-associated vasculitis. (makol2014vasculitisassociatedwith pages 1-1, makol2015rheumatoidvasculitisan pages 7-8)
Genetic associations described in review literature include enrichment of KIR2DS2 (with relevant HLA ligands) and associations with shared-epitope HLA-DRB1 genotypes; these are best viewed as susceptibility associations rather than deterministic causes. (kishore2017rheumatoidvasculitisa pages 2-4)
In the Mayo case-control study, hydroxychloroquine (OR 0.54) and low-dose aspirin (OR 0.42) were associated with decreased odds of RV. These findings are observational and do not prove causality. (makol2014vasculitisassociatedwith pages 1-1)
Smoking is consistently implicated as a risk factor; reviews hypothesize that smoking may promote endothelial dysfunction and immune activation pathways (B- and T-cell–mediated damage), although direct gene–environment interaction quantification for RV was not available in retrieved sources. (kishore2017rheumatoidvasculitisa pages 2-4)
RV most commonly affects the skin and peripheral nervous system. - Reviews report skin involvement ~90% and emphasize a spectrum from nailfold infarcts to deep ulcers and digital ischemia. (kishore2017rheumatoidvasculitisa pages 1-2) - Peripheral nervous system involvement (e.g., vasculitic neuropathy / mononeuritis multiplex) is a classic severe presentation. (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 3-5)
A real-world rituximab-treated Mayo cohort (17 RV patients, 2000–2017) reported: - Skin involvement in 47% (ulcers and/or leukocytoclastic vasculitis). (coffey2020rituximabtherapyfor pages 7-9) - Mononeuritis multiplex in 12%. (coffey2020rituximabtherapyfor pages 7-9) - Inflammatory ocular disease in 12%. (coffey2020rituximabtherapyfor pages 7-9) - Multi-organ involvement in 29%. (coffey2020rituximabtherapyfor pages 7-9)
A 2024 case-based review notes that skin and peripheral nervous system involvement are common and also reports approximate frequencies for other systems (cardiovascular, eyes) in the broader RV literature. (ahmad2024rheumatoidvasculitisin media ab2cb492)
RV usually arises after years of RA (reviewed mean ~10–14 years from RA diagnosis), but recent case literature highlights that RV can occasionally present early or even precede overt RA diagnosis. (makol2015rheumatoidvasculitisan pages 3-5, karra2024rheumatoidvasculitisinvolving pages 7-8)
The following HPO concepts map well to commonly described RV manifestations (ontology IDs not retrieved in this run; labels provided): - Cutaneous ulcer; Digital ischemia; Purpura; Skin vasculitis. (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) - Mononeuritis multiplex; Peripheral neuropathy. (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) - Scleritis / Episcleritis; Keratitis / Corneal melt. (coffey2020rituximabtherapyfor pages 7-9) - Fever; Weight loss; Elevated inflammatory markers (ESR/CRP). (makol2015rheumatoidvasculitisan pages 5-7, ahmad2024rheumatoidvasculitisin media 15865f42)
RV is not a monogenic disorder in the retrieved literature; it is best understood as a complex, multifactorial complication of RA with genetic susceptibility signals rather than a single causal gene. (kishore2017rheumatoidvasculitisa pages 2-4)
Variant-level (ClinVar/gnomAD) data were not retrieved for RV in this run.
Smoking is a consistent clinical risk factor supported by case-control evidence and review synthesis. (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 2-4)
Other environmental triggers (e.g., infections, drug exposures) are discussed in review literature primarily as potential triggers or confounders; distinguishing RA-associated RV from drug-induced vasculitis (notably anti-TNF-associated vasculitis) is emphasized as an ongoing clinical challenge. (makol2015rheumatoidvasculitisan pages 7-8, makol2015rheumatoidvasculitisan pages 5-7)
A commonly synthesized pathway is: 1) Seropositive RA with high autoantibody burden (RF and often ACPA/anti-CCP), associated with circulating immune complexes. (makol2015rheumatoidvasculitisan pages 3-5, bartels2010rheumatoidvasculitisvanishing pages 4-5) 2) Immune complex deposition in vessel walls with complement activation and Fc receptor engagement, leading to leukocyte activation and cytokine release. (kishore2017rheumatoidvasculitisa pages 1-2, genta2006systemicrheumatoidvasculitis pages 2-3) 3) Endothelial activation/injury (adhesion molecule expression such as ICAM-1 and E-selectin) and recruitment/activation of inflammatory cells. (kishore2017rheumatoidvasculitisa pages 1-2) 4) Vessel wall necrosis and leukocytoclastic inflammation, causing ischemia, ulceration, neuropathy, and end-organ injury depending on vascular territory. (makol2015rheumatoidvasculitisan pages 3-5)
No RV-specific transcriptomic/proteomic/metabolomic profiling studies were retrieved in this run; this remains a gap relative to RA synovial tissue multi-omics literature.
Predominantly affected systems include: - Skin (cutaneous small-vessel vasculitis, ulcers, digital ischemia). (kishore2017rheumatoidvasculitisa pages 1-2, coffey2020rituximabtherapyfor pages 7-9) - Peripheral nervous system (vasculitic neuropathy, mononeuritis multiplex). (kishore2017rheumatoidvasculitisa pages 1-2, coffey2020rituximabtherapyfor pages 7-9) - Eyes (scleritis/episcleritis, ulcerative keratitis). (coffey2020rituximabtherapyfor pages 7-9)
RV can be multi-organ and can involve GI tract, CNS, heart, kidney, and lung in severe disease (reviewed as possible severe organ targets even when absent in specific cohorts). (makol2015rheumatoidvasculitisan pages 3-5, makol2015rheumatoidvasculitisan pages 5-7)
Skin; peripheral nerve; medium-sized artery; small blood vessel; eye; gastrointestinal tract. (makol2015rheumatoidvasculitisan pages 3-5, makol2015rheumatoidvasculitisan pages 5-7, coffey2020rituximabtherapyfor pages 7-9)
RV is usually adult-onset and most often occurs after prolonged RA duration (mean ~10–14 years in review literature), but early presentations have been reported. (makol2015rheumatoidvasculitisan pages 3-5, karra2024rheumatoidvasculitisinvolving pages 7-8)
RV may be rapidly progressive when systemic/necrotizing arteritis is present, and it has high relapse risk in some cohorts. (makol2014vasculitisassociatedwith pages 1-1, makol2015rheumatoidvasculitisan pages 5-7)
RV incidence has declined markedly over recent decades, likely reflecting improved RA control: - Norfolk/Norwich trend cited in reviews: 9.1/million (1988–2000/2002) vs 3.9/million (2001–2010). (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2) - Olmsted County cumulative incidence in RA reported to decline from 3.6% (1985–1994) to 0.6% (1995–2007). (kishore2017rheumatoidvasculitisa pages 1-2)
A large multicenter cohort of RA patients (Brazilian public rheumatology centers; data collection beginning 2015) reported extra-articular manifestations prevalence 23.4% overall, and reaffirmed that long-standing seropositive disease and disability/inflammatory activity are key correlates of extra-articular disease (the paper is not RV-specific but provides contemporary context that extra-articular disease remains common). (ahmad2024rheumatoidvasculitisin media ab2cb492)
RV diagnosis is typically syndromic and clinicopathologic: - Biopsy with characteristic histopathology is emphasized as important/often necessary when feasible; skin biopsy yields up to ~75% in review data. (makol2015rheumatoidvasculitisan pages 3-5) - When biopsy is not feasible, angiography may be considered for suspected mesenteric or extremity ischemia and mimics should be excluded; treatment may be started on strong clinical suspicion. (makol2015rheumatoidvasculitisan pages 5-7) - A 2024 case-based review stresses that a negative biopsy does not exclude RV and may reflect sampling limitations. (ahmad2024rheumatoidvasculitisin pages 5-6)
Laboratory evaluation is supportive rather than definitive: - Elevated ESR/CRP and cytopenias/inflammation-associated CBC patterns are included in a review algorithm. (makol2015rheumatoidvasculitisan pages 5-7) - RF and ACPA are commonly present but have modest positive predictive value; absence has good negative predictive value. (makol2015rheumatoidvasculitisan pages 3-5)
A rituximab-treated RV cohort also documents real-world diagnostic workup beyond clinical diagnosis, including biopsy, CT angiography, and EMG in subsets. (coffey2020rituximabtherapyfor pages 7-9)
A representative 2024 case workup table (RF/anti-CCP/ESR/CRP, etc.) is available as extracted Table 1. (ahmad2024rheumatoidvasculitisin media 15865f42)
Typical features include mononuclear or neutrophilic vessel wall infiltration with necrosis, leukocytoclasis, and disruption of elastic laminae; perivascular infiltrates without vessel-wall involvement do not meet criteria. (makol2015rheumatoidvasculitisan pages 3-5)
Key mimics include: - Primary ANCA-associated vasculitis, especially when vasculitic neuropathy, skin lesions, or systemic features are present (ANCA patterns in RV can be atypical and MPO/PR3 often negative). (makol2015rheumatoidvasculitisan pages 3-5, bartels2010rheumatoidvasculitisvanishing pages 4-5) - Drug-induced vasculitis (notably anti-TNF-associated vasculitis), which may be suggested by temporal relationship, resolution on withdrawal, and recurrence on rechallenge. (makol2015rheumatoidvasculitisan pages 7-8)
RV remains associated with substantial mortality: - Mayo RA-vasculitis case-control cohort (86 RV cases, 2000–2010): 26% died by 5 years and 36% relapsed by 5 years. (makol2014vasculitisassociatedwith pages 1-1) - Reviews cite registry-era mortality rates as high as 12% at 1 year and 60% at 5 years in one cohort, with infection and active vasculitis/organ damage important causes of death. (makol2015rheumatoidvasculitisan pages 5-7)
Treatment intensity is typically stratified by extent and organ-threatening involvement.
A pragmatic approach includes: - Mild–moderate RV: oral glucocorticoids plus methotrexate or azathioprine. (makol2015rheumatoidvasculitisan pages 5-7) - Severe RV: higher-dose glucocorticoids (± IV pulse) plus cyclophosphamide or rituximab; biologics (including anti-TNF) are discussed, with careful attention to possible drug-induced vasculitis. (makol2015rheumatoidvasculitisan pages 5-7) - Refractory disease: switching biologic class (rituximab, anti-TNF, tocilizumab, abatacept, anakinra) and/or adjunctive plasmapheresis/IVIG may be considered. (makol2015rheumatoidvasculitisan pages 5-7)
In a rituximab-treated systemic RV cohort (17 patients, Mayo Clinic, 2000–2017): - RV presentations included skin (47%), mononeuritis multiplex (12%), ocular disease (12%), and multi-organ disease (29%); rituximab dose commonly 1 g two weeks apart. (coffey2020rituximabtherapyfor pages 7-9) - Outcomes in the abstract: complete remission and partial responses accumulated over 3–12 months (e.g., 40% complete remission at 6 months, 62% complete remission at 12 months). (coffey2020rituximabtherapyfor pages 2-3)
See treatment artifact for suggested MAXO mappings by modality (systemic corticosteroid therapy, cyclophosphamide therapy, rituximab therapy, TNF inhibitor therapy, IVIG therapy, plasmapheresis, etc.). (makol2015rheumatoidvasculitisan pages 5-7, coffey2020rituximabtherapyfor pages 7-9)
No RV-specific primary prevention interventions were identified in the retrieved sources. Given smoking’s association with RV risk, smoking cessation is biologically plausible as risk modification in RA, but RV-specific interventional prevention studies were not retrieved. (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 2-4)
No naturally occurring veterinary analogs or cross-species transmission issues were identified in the retrieved RV-focused sources.
No RV-specific model organism systems were retrieved in this run; mechanistic discussion in reviews is largely based on human clinicopathologic observations and extrapolation from immune complex biology and vascular inflammation paradigms. (kishore2017rheumatoidvasculitisa pages 1-2, genta2006systemicrheumatoidvasculitis pages 2-3)
1) Extra-articular RA remains common in contemporary cohorts: A 2023 multicenter RA cohort found extra-articular manifestations in 23.4% of RA patients and associated extra-articular disease with longer disease duration, high RF titers, higher disease activity, and greater disability, reinforcing that severe systemic RA phenotypes persist despite modern RA therapeutics. (ahmad2024rheumatoidvasculitisin media ab2cb492)
2) Diagnostic challenges persist in the modern era: 2024 case-based literature emphasizes that negative biopsy does not exclude RV, highlighting sampling limitations and the need for multimodal assessment (clinical syndrome + targeted investigations). (ahmad2024rheumatoidvasculitisin pages 5-6)
3) Contemporary practice continues to rely on extrapolation and observational evidence: RV remains too rare for robust RV-specific randomized trials; modern practice increasingly uses biologics (notably rituximab) alongside glucocorticoids, with response data primarily from case series and single-center cohorts. (makol2015rheumatoidvasculitisan pages 5-7, coffey2020rituximabtherapyfor pages 7-9)
| Domain | Summary | Evidence/Citations |
|---|---|---|
| Definition | Rheumatoid vasculitis (RV) is a rare but severe extra-articular manifestation of rheumatoid arthritis, characterized by necrotizing or leukocytoclastic vasculitis affecting predominantly small-to-medium vessels and associated with high morbidity and mortality. | (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) |
| Synonyms / alternative names | Rheumatoid vasculitis; systemic rheumatoid vasculitis; vasculitis associated with rheumatoid arthritis. | (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2) |
| Key identifiers / coding placeholders | ICD-10: not identified in retrieved context; ICD-11: not identified in retrieved context; MeSH: specific RV MeSH term not confirmed in retrieved context; MONDO: not identified in retrieved context; Orphanet: not identified in retrieved context. Retrieved evidence is disease-level literature/reviews and case series rather than ontology registry records. | (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2) |
| Epidemiology: incidence/prevalence trends | Incidence has declined markedly in the modern treatment era. Reported Norfolk/Norwich trend: 9.1/million in 1988–2000/2002 vs 3.9/million in 2001–2010. Olmsted County 10-year cumulative incidence in RA reportedly fell from 3.6% (1985–1994) to 0.6% (1995–2007). Reviews consistently describe RV as “diminishing” or “vanishing,” likely related to better RA control and biologic-era management. | (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2) |
| Prognosis / mortality | Prognosis remains poor despite lower incidence. In the Mayo 2000–2010 case-control cohort, 26% died by 5 years and 36% relapsed by 5 years. A registry/cohort cited in reviews reported 12% mortality at 1 year and 60% at 5 years. Historical reviews note up to 40% mortality within 5 years. | (makol2014vasculitisassociatedwith pages 1-1, makol2015rheumatoidvasculitisan pages 7-8, makol2015rheumatoidvasculitisan pages 5-7) |
| Major risk factors | Long-standing, severe, seropositive, nodular/erosive RA; male sex; older age; smoking; extra-articular RA burden; vascular comorbidity. Effect sizes from Mayo case-control study: current smoking at RA diagnosis OR 1.98; peripheral vascular disease OR 3.98; cerebrovascular disease OR 6.48; severe RA OR 2.02; biologic use OR 2.80. High RF/ACPA titers are repeatedly associated with RV. | (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) |
| Protective factors | Hydroxychloroquine and low-dose aspirin were associated with lower odds of RV in one case-control study: hydroxychloroquine OR 0.54; low-dose aspirin OR 0.42. | (makol2014vasculitisassociatedwith pages 1-1, kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2) |
| Common organ manifestations | Skin and peripheral nerves are the dominant targets. Approximate frequencies from review/case-based literature: skin ~90% of cases; peripheral nervous system ~40%; cardiovascular system ~30%; eye involvement ~15%. In the rituximab cohort: skin 47%, mononeuritis multiplex 12%, inflammatory ocular disease 12%, multi-organ involvement 29%; no renal or pulmonary vasculitis in that series. | (kishore2017rheumatoidvasculitisa pages 1-2, ahmad2024rheumatoidvasculitisin media ab2cb492, coffey2020rituximabtherapyfor pages 7-9) |
| Examples of cutaneous/neurologic phenotypes | Nail-fold infarcts, palpable purpura, deep/non-healing leg ulcers, pyoderma gangrenosum-like lesions, digital ischemia/gangrene; vasculitic neuropathy/mononeuritis multiplex are emphasized as classic presentations. | (kishore2017rheumatoidvasculitisa pages 1-2, makol2015rheumatoidvasculitisan pages 1-2, makol2015rheumatoidvasculitisan pages 3-5) |
| Diagnostic hallmarks (compact) | Diagnosis is primarily clinical-pathologic: biopsy showing necrotizing/leukocytoclastic vasculitis when feasible; skin biopsy yield up to ~75% in review data. Supportive labs include high RF/ACPA, elevated ESR/CRP, low complement; angiography may help in medium-vessel or ischemic disease; negative biopsy does not exclude RV if suspicion remains high. | (makol2015rheumatoidvasculitisan pages 3-5, makol2015rheumatoidvasculitisan pages 5-7, ahmad2024rheumatoidvasculitisin pages 5-6, ahmad2024rheumatoidvasculitisin media 15865f42) |
Table: This table condenses the most actionable disease-characteristics evidence for rheumatoid vasculitis from the retrieved context, including definition, coding gaps, epidemiology, prognosis, risk/protective factors, and organ manifestations.
| Disease severity / scenario | Treatment option | Regimen components / typical dosing stated in sources | Key outcome data / use case | Suggested MAXO term(s) | Evidence |
|---|---|---|---|---|---|
| Mild–moderate RV (limited cutaneous disease, pericarditis, 0–1 extra-articular manifestations) | Glucocorticoids + methotrexate | Oral glucocorticoids 20–40 mg/day prednisone equivalent + methotrexate 10–25 mg/week (first-line oral DMARD) | Recommended empiric induction approach for limited disease; used because patients with primarily limited cutaneous disease may respond to lesser immunosuppression | MAXO: systemic corticosteroid therapy; methotrexate therapy; immunosuppressive therapy | (makol2015rheumatoidvasculitisan pages 5-7) |
| Mild–moderate RV when methotrexate unsuitable | Glucocorticoids + azathioprine | Oral glucocorticoids 20–40 mg/day prednisone equivalent + azathioprine 2 mg/kg/day (alternative oral DMARD) | Alternative induction regimen for limited disease in review-based treatment algorithm | MAXO: systemic corticosteroid therapy; azathioprine therapy; immunosuppressive therapy | (makol2015rheumatoidvasculitisan pages 5-7) |
| Severe/systemic RV (multi-organ disease, necrotizing arteritis, major end-organ involvement) | High-dose glucocorticoids + cyclophosphamide | Oral glucocorticoids 40–60 mg/day prednisone equivalent and/or IV pulse glucocorticoids 0.5–1 g/day for 3 days + cyclophosphamide (daily oral or monthly IV) for ~3–6 months in algorithm text | Historical standard for severe RV; still used for life-threatening disease, but toxicity remains substantial and mortality in older cohorts remained high | MAXO: intravenous methylprednisolone therapy; cyclophosphamide therapy; remission induction therapy | (makol2015rheumatoidvasculitisan pages 5-7, bartels2010rheumatoidvasculitisvanishing pages 4-5) |
| Severe/systemic RV | Rituximab-based induction | Rituximab 1 g IV 2 weeks apart in review algorithm; in Mayo series, 1 g 2 weeks apart in 13/15 treated with standard schedule, with 2 receiving 375 mg/m2 weekly ×4; often combined with glucocorticoids, sometimes DMARDs | Mayo 17-patient cohort: CR 13% and PR 67% at 3 months; CR 40% and PR 53% at 6 months; CR 62% and PR 38% at 12 months. French registry cited in review: 12/17 complete remissions at 6 months; 14/17 in remission at 12 months; severe infection rate 6.4/100 patient-years. | MAXO: rituximab therapy; B-cell depletion therapy; remission induction therapy | (coffey2020rituximabtherapyfor pages 2-3, makol2015rheumatoidvasculitisan pages 3-5, makol2015rheumatoidvasculitisan pages 5-7, coffey2020rituximabtherapyfor pages 7-9) |
| Maintenance after rituximab response / relapse prevention | Rituximab maintenance or conventional DMARD maintenance | Review algorithm suggests MTX/AZA/LEF/rituximab maintenance; in cited rituximab registry, some patients received additional rituximab between months 6 and 12 | In review-cited registry, no relapse among 6 patients who received maintenance rituximab between months 6 and 12, versus 3 relapses among 9 without it; remission reestablished after reintroduction in 2 cases | MAXO: maintenance immunotherapy; rituximab therapy; methotrexate therapy; azathioprine therapy; leflunomide therapy | (makol2015rheumatoidvasculitisan pages 5-7) |
| Severe or refractory RV | Anti-TNF therapy | Review algorithm lists anti-TNF agent as an option for severe RV; specific dosing not standardized in retrieved RV sources | Case reports/series describe successful use in refractory RV, but role is controversial because >200 cases of anti-TNF–associated vasculitis have also been reported; if drug-induced vasculitis suspected, stop and switch biologic | MAXO: TNF inhibitor therapy; biologic immunomodulator therapy | (makol2015rheumatoidvasculitisan pages 5-7, makol2015rheumatoidvasculitisan pages 7-8) |
| Refractory / relapsing RV | Tocilizumab | Listed in review as alternate biologic for refractory disease; dosing not specified in retrieved RV sources | Supported mainly by case reports/limited experience; reserved for refractory disease after standard agents | MAXO: tocilizumab therapy; interleukin-6 inhibitor therapy | (makol2015rheumatoidvasculitisan pages 7-8, makol2015rheumatoidvasculitisan pages 5-7) |
| Refractory / relapsing RV | Abatacept | Listed in review as alternate biologic for refractory disease; dosing not specified in retrieved RV sources | Supported mainly by case reports/limited experience; reserved for refractory disease after standard agents | MAXO: abatacept therapy; T-cell costimulation modulator therapy | (makol2015rheumatoidvasculitisan pages 7-8, makol2015rheumatoidvasculitisan pages 5-7) |
| Refractory / relapsing RV | Anakinra | Listed in review algorithm as possible alternate biologic; dosing not specified in retrieved RV sources | Very limited evidence/case-report level in RV | MAXO: anakinra therapy; interleukin-1 inhibitor therapy | (makol2015rheumatoidvasculitisan pages 5-7) |
| Refractory, relapsing, or life-threatening RV adjunctive therapy | IVIG and/or plasmapheresis | Review algorithm recommends addition of plasmapheresis or IVIG in refractory cases; dosing not specified in retrieved RV sources | Adjunctive/salvage role rather than standard first-line treatment | MAXO: intravenous immunoglobulin therapy; plasmapheresis | (makol2015rheumatoidvasculitisan pages 5-7) |
| Contemporary real-world treatment mix (Mayo 2000–2010 RV cohort) | Observed multimodal practice | 99% received glucocorticoids; 29% cyclophosphamide; 55% another DMARD (methotrexate, azathioprine, mycophenolate mofetil, hydroxychloroquine, minocycline); 28% biologic agent (anti-TNF, rituximab, abatacept, anakinra) | Demonstrates real-world heterogeneity and lack of controlled RV-specific trials; therapy individualized by organ involvement and severity | MAXO: immunosuppressive therapy; biologic therapy; glucocorticoid therapy | (makol2015rheumatoidvasculitisan pages 5-7) |
Table: This table summarizes rheumatoid vasculitis treatments by disease severity, including dosing details reported in the retrieved sources, outcome data where available, and suggested MAXO mappings. It is useful for converting narrative review evidence into a structured treatment knowledge-base artifact.
References
(kishore2017rheumatoidvasculitisa pages 1-2): Shweta Kishore, Lisa Maher, and Vikas Majithia. Rheumatoid vasculitis: a diminishing yet devastating menace. Current Rheumatology Reports, 19:1-7, Jun 2017. URL: https://doi.org/10.1007/s11926-017-0667-3, doi:10.1007/s11926-017-0667-3. This article has 85 citations and is from a peer-reviewed journal.
(makol2015rheumatoidvasculitisan pages 1-2): Ashima Makol, Eric L. Matteson, and Kenneth J. Warrington. Rheumatoid vasculitis: an update. Current Opinion in Rheumatology, 27:63–70, Jan 2015. URL: https://doi.org/10.1097/bor.0000000000000126, doi:10.1097/bor.0000000000000126. This article has 158 citations and is from a peer-reviewed journal.
(makol2015rheumatoidvasculitisan pages 3-5): Ashima Makol, Eric L. Matteson, and Kenneth J. Warrington. Rheumatoid vasculitis: an update. Current Opinion in Rheumatology, 27:63–70, Jan 2015. URL: https://doi.org/10.1097/bor.0000000000000126, doi:10.1097/bor.0000000000000126. This article has 158 citations and is from a peer-reviewed journal.
(makol2014vasculitisassociatedwith pages 1-1): A. Makol, C. S. Crowson, D. A. Wetter, O. Sokumbi, E. L. Matteson, and K. J. Warrington. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology, 53:890-899, Jan 2014. URL: https://doi.org/10.1093/rheumatology/ket475, doi:10.1093/rheumatology/ket475. This article has 155 citations and is from a peer-reviewed journal.
(coffey2020rituximabtherapyfor pages 7-9): Caitrin M. Coffey, Michael D. Richter, Cynthia S. Crowson, Matthew J. Koster, Kenneth J. Warrington, Steven R. Ytterberg, and Ashima Makol. Rituximab therapy for systemic rheumatoid vasculitis: indications, outcomes, and adverse events. The Journal of Rheumatology, 47:518-523, Apr 2020. URL: https://doi.org/10.3899/jrheum.181397, doi:10.3899/jrheum.181397. This article has 30 citations.
(coffey2020rituximabtherapyfor pages 2-3): Caitrin M. Coffey, Michael D. Richter, Cynthia S. Crowson, Matthew J. Koster, Kenneth J. Warrington, Steven R. Ytterberg, and Ashima Makol. Rituximab therapy for systemic rheumatoid vasculitis: indications, outcomes, and adverse events. The Journal of Rheumatology, 47:518-523, Apr 2020. URL: https://doi.org/10.3899/jrheum.181397, doi:10.3899/jrheum.181397. This article has 30 citations.
(ahmad2024rheumatoidvasculitisin pages 5-6): Anam Ahmad, Farina Tariq, and Muhammad Zaheer. Rheumatoid vasculitis in modern era: a case report and comprehensive literature review. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.62783, doi:10.7759/cureus.62783. This article has 1 citations.
(ahmad2024rheumatoidvasculitisin media 15865f42): Anam Ahmad, Farina Tariq, and Muhammad Zaheer. Rheumatoid vasculitis in modern era: a case report and comprehensive literature review. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.62783, doi:10.7759/cureus.62783. This article has 1 citations.
(genta2006systemicrheumatoidvasculitis pages 2-3): Marcia S. Genta, Robert M. Genta, and Cem Gabay. Systemic rheumatoid vasculitis: a review. Seminars in arthritis and rheumatism, 36 2:88-98, Oct 2006. URL: https://doi.org/10.1016/j.semarthrit.2006.04.006, doi:10.1016/j.semarthrit.2006.04.006. This article has 262 citations and is from a peer-reviewed journal.
(kishore2017rheumatoidvasculitisa pages 2-4): Shweta Kishore, Lisa Maher, and Vikas Majithia. Rheumatoid vasculitis: a diminishing yet devastating menace. Current Rheumatology Reports, 19:1-7, Jun 2017. URL: https://doi.org/10.1007/s11926-017-0667-3, doi:10.1007/s11926-017-0667-3. This article has 85 citations and is from a peer-reviewed journal.
(makol2015rheumatoidvasculitisan pages 7-8): Ashima Makol, Eric L. Matteson, and Kenneth J. Warrington. Rheumatoid vasculitis: an update. Current Opinion in Rheumatology, 27:63–70, Jan 2015. URL: https://doi.org/10.1097/bor.0000000000000126, doi:10.1097/bor.0000000000000126. This article has 158 citations and is from a peer-reviewed journal.
(ahmad2024rheumatoidvasculitisin media ab2cb492): Anam Ahmad, Farina Tariq, and Muhammad Zaheer. Rheumatoid vasculitis in modern era: a case report and comprehensive literature review. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.62783, doi:10.7759/cureus.62783. This article has 1 citations.
(karra2024rheumatoidvasculitisinvolving pages 7-8): Nanditha Karra, Sumith Mustyala, Sritej Reddy Meghi, FNU Safa, Siri Sanmayi Medicherla, Ajay Goud Nattala, Jai Hind Reddy Nalla, and Rajendraprasad Saligommula. Rheumatoid vasculitis involving gastrointestinal tract pre-dating rheumatoid arthritis: a case study and literature review. Cureus, Aug 2024. URL: https://doi.org/10.7759/cureus.67346, doi:10.7759/cureus.67346. This article has 2 citations.
(makol2015rheumatoidvasculitisan pages 5-7): Ashima Makol, Eric L. Matteson, and Kenneth J. Warrington. Rheumatoid vasculitis: an update. Current Opinion in Rheumatology, 27:63–70, Jan 2015. URL: https://doi.org/10.1097/bor.0000000000000126, doi:10.1097/bor.0000000000000126. This article has 158 citations and is from a peer-reviewed journal.
(bartels2010rheumatoidvasculitisvanishing pages 4-5): Christie M. Bartels and Alan J. Bridges. Rheumatoid vasculitis: vanishing menace or target for new treatments? Current Rheumatology Reports, 12:414-419, Sep 2010. URL: https://doi.org/10.1007/s11926-010-0130-1, doi:10.1007/s11926-010-0130-1. This article has 107 citations and is from a peer-reviewed journal.